Author(s)

Sijia Chen, Yujie Lu, Xiang Yin

Corresponding Author

Sijia Chen

ABSTRACT

The immunotherapy of cancer has been a popular topic and has been developing very fast in recent years. Chimeric antigen receptor T cell therapy, as known as CAR T cell therapy is an adoptive cell therapy that modifies the T cells from the patient with specific receptors which can recognise the antigen on the surface of tumour cells, reinject the T cells back in order to kill the tumour cells efficiently. This fantastic way of modifying the patient's T cells to fight cancer has shown its value in treating B-cell malignancies and Multiple myeloma with remarkable efficiency. Further generation of CAR-T cell therapy should aim for reduced patient expenditure and side effects to encounter associated challenges. This review introduced the mechanism of the CAR-T cell therapy, the targeted cancers, challenges, and the future of the therapy.

KEYWORDS

Adoptive cell therapy, Malignancies, tumour immunotherapy